Biocon

Bengaluru: Biocon Malaysia has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK, for its new drug product fill-finish unit for Semglee (insulin glargine) at...

UK regulator approval follows EMA clearances, enabling Biocon's Malaysia-based fill-finish line to support aseptic packaging and final delivery of Semglee insulin and other biologics

NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Bengaluru, Karnataka, India, September 25, 2026 Biocon Limited (BSE code: 532523, NSE: BIOCON) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

Biocon Biologics: Biocon's Pertuzumab has received a positive EMA CHMP recommendation, becoming the first biosimilar to clear the agency's new tailored clinical development approach for HER2-positive breast cancer

Bengaluru, Karnataka, India, September 21, 2026 Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines

Bengaluru, Karnataka, India: September 8, 2026: Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil

NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Bengaluru, Karnataka, India, August 25, 2026 Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), received marketing approval for its pegfilgrastim biosimilar ("P

NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Bengaluru, Karnataka, India, August 18, 2026 Biocon Limited's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek 45 mg/0.5 ml single-dose